The results showed that clinical responses continued to improve from Week 16 through Week 52 and were maintained through Week 104 among patients receiving Sotyktu
Summit happening on September 24 to bring together healthcare, pharma and biotech leaders to discuss GCCs, genomics, biotechnology and India’s evolving role in global life sciences
Royalty-free licence to support manufacturing readiness, technology transfer and future supply planning in licensed markets
The treatment also produced significant changes across several blood-lipid measures
Leading experts to discuss challenges associated with complex therapeutics, including peptides, oligonucleotides and long-acting injectables at Peptides & Complex Generics Symposium 2026 in Mumbai on September 28–29, 2026
Company shares its capabilities across R&D, complex medicines and biosimilars following the acquisition of Kashiv Biosciences
The experimental therapy is designed to target T cells and two tumour-associated antigens simultaneously
The deal will also transfer three Sanofi manufacturing facilities to Cheplapharm: Csanyikvölgy in Hungary, Jurong in Singapore and Ploërmel in France
Ozone Shield provides security assistance, legal assistance and emotional wellbeing support to doctors in case they get caught in such an untoward scenario
The drug acts through a unique dual mechanism of action, selectively inhibiting the persistent sodium current that drives repetitive neuronal firing
Transfer of API and intermediates business to RPG Active Pharma effective September 16, 2026
Collaboration will focus on QurCan’s non-viral delivery platform, with potential milestone payments of up to $237 million per programme
VitiPure portfolio targets pharmacopoeia-grade, low-endotoxin and stability-critical applications, while US facility strengthens regional PEG supply
The healthcare company has unveiled a sweeping rebrand centred on ‘Lasting Health Starts Now’, alongside a move toward the single ‘Novo’ name
The acquisition, approved at the Board meeting held on September 13, 2026, is intended to streamline company’s corporate structure by removing multiple layers of ownership
Calculated on a diluted basis, the promoter and promoter group's combined holding works out to 37.39%
The inspection was conducted over five days at the API manufacturing unit located in the Industrial Development Area, Pydibhimavaram, Ranasthalam Mandal, Srikakulam District, Andhra Pradesh
Also to expand precision genetic medicines pipeline
ACHEMA 2027 will provide Indian industry participants with opportunities to engage directly with global technology providers, researchers, decision-makers and business leaders
The question confronting healthcare leaders is no longer simply how to manage change, but how to influence it
Subscribe To Our Newsletter & Stay Updated
